Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October
“Wet AMD is an aggressive disease that often requires frequent anti-VEGF injections over the long-term in order to reduce vision loss,” said
Podium Presentation: 24-week Results of Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial)
Abstract #: 30062032
Section: Section VIII: Late Breaking Developments, Part I
Location: Moscone Center,
Speaker: Szilard Kiss, M.D., director of clinical research in the
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.
Investor and Media Inquiries: Investors:
Myesha LacyInvestor Relations and Corporate Communications firstname.lastname@example.org 650-304-3892 Media: Joshua R. MansbachSolebury Trout email@example.com 646-378-2964
Source: Adverum Biotechnologies, Inc.